search
Back to results

Skeletal Response to Simulated Night Shift (SPOTLIGHT)

Primary Purpose

Osteoporosis, Circadian Rhythm Sleep Disorder, Shift Work Type

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Simulated short term night shift work schedule
Sponsored by
University of Colorado, Denver
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Osteoporosis

Eligibility Criteria

20 Years - 40 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria

  • Healthy, nonpregnant adults 20-40 years old who habitually sleep 7-9 hours during the biological night

    o Women must be premenopausal, on continuous combination oral contraception and not breastfeeding.

  • Willing and able to complete a sleep diary, wear a wrist actigraphy monitor and complete a 3-6 week research study including two 4-night inpatient stays.
  • Fully vaccinated against SARS-CoV-2, and willing to produce a negative COVID test result before their first inpatient stay.

Exclusion Criteria

  • Regularly go to sleep after midnight.
  • Night shift work within 1 year prior to study.
  • Travel > 1 time zone within 4 weeks prior to the study or need to travel >1 time zone during study.
  • Physical activity level/regimen incompatible with inpatient CTRC stay.
  • Current smokers (or within the previous year of study)
  • Positive drug test at screening or inpatient admission
  • BMI > 30 kg/m2
  • Individuals who are concurrently participating in another research protocol that would influence their safe participation in this study. For example, participants involved in a study that requires blood draws or ingestion of experimental medication as this would increase the risk of participation in our study and/or compromise study results.
  • Any clinically significant unstable medical or surgical condition within the last year (treated or untreated), including history of a clinically significant abnormality of the neurological system (including cognitive disorders or significant head injury) or any history of seizure (including febrile seizure-sleep loss has been used clinically to induce seizures in patients with epilepsy). Given the wide range of illnesses that are encountered in medical practice, it would not be possible to provide a comprehensive list of each and every disease that could serve as grounds for exclusion for the subject. However, the following is a list of illness categories that would certainly be grounds for exclusion: Connective Tissue and Joint Disorders; Neurologic/cognitive Disorders; Musculoskeletal Disorders; Immune Disorders; Chronobiologic Disorders; Cardiovascular Disorders; Respiratory Disorders; Kidney Disorders; Infectious Diseases; Hematopoietic Disorders; Neoplastic Diseases; and Endocrine and Metabolic Diseases.
  • Self-reported or newly diagnosed medical condition that is still being investigated or is not under good control, including those identified on screening labs such as:

    o Out-of-range values measured on a fasting blood sample: glucose > 100 mg/dl, thyroid stimulating hormone <0.5 or >5.0 uU/ml, abnormal alkaline phosphatase <39 or >117 U/l, creatinine, or hemoglobin <14.5 g/dl men

  • Any clinically significant psychiatric condition, as defined by DSM-V. Individuals with a history of most psychiatric illnesses or psychiatric disorders will be excluded, such as but not limited to depression, anxiety, alcoholism, drug dependency, schizophrenic disorders, and personality disorders (performed by medical history and physician interview). However, a personal history of limited prior counseling, psychotherapy (e.g., for adjustment reactions) will NOT be exclusionary.
  • Evaluation of Psychiatric/Psychological Suitability:

    • Inability to demonstrate a full understanding of the requirements and demands of the study.
    • Each participant will complete psychological screening questionnaires. Exclusionary: Center for Epidemiological Studies Depression (CES-D) > 16. Subject responses to the CES-D are reviewed immediately and appropriate referrals are made if necessary.
    • Individuals who are unaware of specific psychiatric diagnoses who have a history of having been treated with antidepressants, neuroleptic medications or major tranquilizers will be excluded from study.
    • Use of anti-depressants or any like therapeutics prescribed by a physician is exclusionary
  • Individuals with any clinically significant sleep disorder; Diagnosis or symptoms of sleep disorders (history of significant parasomnia as an adult [night terrors, frequent sleep walking], insomnia, including but not limited to hypersomnias such as apnea, periodic limb movements, narcolepsy). Sleep disorders will be screened by self-report and physician interview including use of validated sleep questionnaires (PSQI, Epworth sleepiness scale, and Berlin sleep questionnaire for sleep apnea). The following scores will be used to exclude those with sleep disorders: PSQI >5, Epworth Sleepiness Scale >9.
  • Individuals on medications known to affect bone turnover (e.g., glucocorticoids, osteoporosis medications);
  • Use of medications/supplements/drugs that impact sleep or bone metabolism (such as but not limited to sleep medications, marijuana, etc.) within one month (participants can be studied at a later date).
  • Dwelling below Denver altitude (1,600 m) 1 month prior to enrollment.
  • Greater than moderate caffeine (>500 mg/day) or alcohol use (>14 standard drinks/ week or >5 drinks in one sitting)
  • Inability to travel to the CU-AMC campus for study visits.
  • Individuals with restrictive diets (e.g., vegan)
  • Individuals with 25OHD < 20 ng/mL (may be studied at a later date)
  • Individuals with eGFR < 60 mL/min/1.73m2 as this is known to affect CTX measurements.
  • Z-score < -2.0 for bone mineral density at the L-spine, femoral neck, or total hip on baseline DXA as compared to the DXA machine's normative database.
  • Symptoms of active illness (e.g., fever) at time of enrollment; note - participant may be studied at a later date.
  • Restrictive diets that cannot be accommodated by the CTRC Nutrition Core
  • Any other reason that participant may not be able to safely complete the entire study, at PI discretion

Sites / Locations

  • CU AnschutzRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control (8 hours nocturnal sleep)

Simulated Night Shift Work

Arm Description

Inpatient protocol involves 8-hour sleep opportunity during the biological night throughout.

Two inpatient stays, each involving a baseline night, followed by a 3-hour afternoon nap opportunity, and then three 12-hour night shifts, with 8-hour daytime sleep opportunity in between.

Outcomes

Primary Outcome Measures

Difference in change in propeptide of type 1 procollagen (P1NP)
Difference in change in propeptide of type 1 procollagen (P1NP, a bone formation marker) from baseline to day 11 between the control and simulated NSW groups.

Secondary Outcome Measures

Between-group differences in the change in osteocalcin.
Between-group differences in the change in another bone formation marker (osteocalcin)
Between-group differences in the change in CTX (C-telopeptide of type I collagen)
Between-group differences in the change in bone resorption marker (CTX)

Full Information

First Posted
September 29, 2021
Last Updated
October 19, 2023
Sponsor
University of Colorado, Denver
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT05074277
Brief Title
Skeletal Response to Simulated Night Shift
Acronym
SPOTLIGHT
Official Title
Skeletal Response to Simulated Night Shift (SPOTLIGHT Study)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 28, 2022 (Actual)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
July 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This small intervention study will determine if simulated short-term night shift work (NSW) negatively alters bone metabolism. The specific aim of the study is to determine if NSW acutely uncouples bone turnover markers (BTMs), if sympathetic tone is a mechanism for this disruption and if a resumption of a normal sleep/wake pattern reverses BTM uncoupling. Our hypothesis is that NSW will reversibly uncouple BTMs via increased sympathetic nervous system (SNS) tone.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoporosis, Circadian Rhythm Sleep Disorder, Shift Work Type

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control (8 hours nocturnal sleep)
Arm Type
No Intervention
Arm Description
Inpatient protocol involves 8-hour sleep opportunity during the biological night throughout.
Arm Title
Simulated Night Shift Work
Arm Type
Experimental
Arm Description
Two inpatient stays, each involving a baseline night, followed by a 3-hour afternoon nap opportunity, and then three 12-hour night shifts, with 8-hour daytime sleep opportunity in between.
Intervention Type
Behavioral
Intervention Name(s)
Simulated short term night shift work schedule
Intervention Description
Participant sleep schedules (in the experimental arm) will be modified to simulate short-term (3 consecutive nights) night shift work schedule (kept awake at night and offered sleep opportunities during the day instead) in each of two inpatient stays.
Primary Outcome Measure Information:
Title
Difference in change in propeptide of type 1 procollagen (P1NP)
Description
Difference in change in propeptide of type 1 procollagen (P1NP, a bone formation marker) from baseline to day 11 between the control and simulated NSW groups.
Time Frame
Baseline to day 11
Secondary Outcome Measure Information:
Title
Between-group differences in the change in osteocalcin.
Description
Between-group differences in the change in another bone formation marker (osteocalcin)
Time Frame
Baseline to day 11
Title
Between-group differences in the change in CTX (C-telopeptide of type I collagen)
Description
Between-group differences in the change in bone resorption marker (CTX)
Time Frame
Baseline to day 11

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria Healthy, nonpregnant adults 20-40 years old who habitually sleep 7-9 hours during the biological night o Women must be premenopausal, on continuous combination oral contraception and not breastfeeding. Willing and able to complete a sleep diary, wear a wrist actigraphy monitor and complete a 3-6 week research study including two 4-night inpatient stays. Fully vaccinated against SARS-CoV-2, and willing to produce a negative COVID test result before their first inpatient stay. Exclusion Criteria Regularly go to sleep after midnight. Night shift work within 1 year prior to study. Travel > 1 time zone within 4 weeks prior to the study or need to travel >1 time zone during study. Physical activity level/regimen incompatible with inpatient CTRC stay. Current smokers (or within the previous year of study) Positive drug test at screening or inpatient admission BMI > 30 kg/m2 Individuals who are concurrently participating in another research protocol that would influence their safe participation in this study. For example, participants involved in a study that requires blood draws or ingestion of experimental medication as this would increase the risk of participation in our study and/or compromise study results. Any clinically significant unstable medical or surgical condition within the last year (treated or untreated), including history of a clinically significant abnormality of the neurological system (including cognitive disorders or significant head injury) or any history of seizure (including febrile seizure-sleep loss has been used clinically to induce seizures in patients with epilepsy). Given the wide range of illnesses that are encountered in medical practice, it would not be possible to provide a comprehensive list of each and every disease that could serve as grounds for exclusion for the subject. However, the following is a list of illness categories that would certainly be grounds for exclusion: Connective Tissue and Joint Disorders; Neurologic/cognitive Disorders; Musculoskeletal Disorders; Immune Disorders; Chronobiologic Disorders; Cardiovascular Disorders; Respiratory Disorders; Kidney Disorders; Infectious Diseases; Hematopoietic Disorders; Neoplastic Diseases; and Endocrine and Metabolic Diseases. Self-reported or newly diagnosed medical condition that is still being investigated or is not under good control, including those identified on screening labs such as: o Out-of-range values measured on a fasting blood sample: glucose > 100 mg/dl, thyroid stimulating hormone <0.5 or >5.0 uU/ml, abnormal alkaline phosphatase <39 or >117 U/l, creatinine, or hemoglobin <14.5 g/dl men Any clinically significant psychiatric condition, as defined by DSM-V. Individuals with a history of most psychiatric illnesses or psychiatric disorders will be excluded, such as but not limited to depression, anxiety, alcoholism, drug dependency, schizophrenic disorders, and personality disorders (performed by medical history and physician interview). However, a personal history of limited prior counseling, psychotherapy (e.g., for adjustment reactions) will NOT be exclusionary. Evaluation of Psychiatric/Psychological Suitability: Inability to demonstrate a full understanding of the requirements and demands of the study. Each participant will complete psychological screening questionnaires. Exclusionary: Center for Epidemiological Studies Depression (CES-D) > 16. Subject responses to the CES-D are reviewed immediately and appropriate referrals are made if necessary. Individuals who are unaware of specific psychiatric diagnoses who have a history of having been treated with antidepressants, neuroleptic medications or major tranquilizers will be excluded from study. Use of anti-depressants or any like therapeutics prescribed by a physician is exclusionary Individuals with any clinically significant sleep disorder; Diagnosis or symptoms of sleep disorders (history of significant parasomnia as an adult [night terrors, frequent sleep walking], insomnia, including but not limited to hypersomnias such as apnea, periodic limb movements, narcolepsy). Sleep disorders will be screened by self-report and physician interview including use of validated sleep questionnaires (PSQI, Epworth sleepiness scale, and Berlin sleep questionnaire for sleep apnea). The following scores will be used to exclude those with sleep disorders: PSQI >5, Epworth Sleepiness Scale >9. Individuals on medications known to affect bone turnover (e.g., glucocorticoids, osteoporosis medications); Use of medications/supplements/drugs that impact sleep or bone metabolism (such as but not limited to sleep medications, marijuana, etc.) within one month (participants can be studied at a later date). Dwelling below Denver altitude (1,600 m) 1 month prior to enrollment. Greater than moderate caffeine (>500 mg/day) or alcohol use (>14 standard drinks/ week or >5 drinks in one sitting) Inability to travel to the CU-AMC campus for study visits. Individuals with restrictive diets (e.g., vegan) Individuals with 25OHD < 20 ng/mL (may be studied at a later date) Individuals with eGFR < 60 mL/min/1.73m2 as this is known to affect CTX measurements. Z-score < -2.0 for bone mineral density at the L-spine, femoral neck, or total hip on baseline DXA as compared to the DXA machine's normative database. Symptoms of active illness (e.g., fever) at time of enrollment; note - participant may be studied at a later date. Restrictive diets that cannot be accommodated by the CTRC Nutrition Core Any other reason that participant may not be able to safely complete the entire study, at PI discretion
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Arpi Bocchieriyan, BS
Phone
303-724-8966
Email
arpi.bocchieriyan@cuanschutz.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Christine M Swanson, MD, MCR
Phone
303-724-0073
Email
christine.swanson@cuanschutz.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christine M Swanson, MD, MCR
Organizational Affiliation
CU Anschutz
Official's Role
Principal Investigator
Facility Information:
Facility Name
CU Anschutz
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Arpi Bocchieriyan, BS
Phone
303-724-8966
Email
arpi.bocchieriyan@cuanschutz.edu
First Name & Middle Initial & Last Name & Degree
SPOTLIGHT
Email
spotlight@ucdenver.edu
First Name & Middle Initial & Last Name & Degree
Christine M Swanson, MD, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Skeletal Response to Simulated Night Shift

We'll reach out to this number within 24 hrs